PRP (Platelet-Rich Plasma) inhalation therapy is a novel, non-surgical technique aimed at promoting tissue repair in the respiratory tract, especially in chronic conditions such as COPD, asthma, or damaged mucosa. A sample of the patient’s blood is taken, centrifuged to concentrate the platelets, and the resulting plasma—rich in growth factors—is nebulized and inhaled through a respiratory mask or delivered via bronchoscopy to target the bronchi directly.
This therapy is used as an adjunctive treatment in patients with chronic bronchial inflammation, persistent airway irritation, or delayed mucosal healing. It can also be helpful in enhancing post-procedural recovery and improving respiratory function in patients with treatment-resistant airway inflammation.
Since PRP is derived from the patient’s own blood, there is minimal risk of allergic reaction or immune rejection. It supports regeneration of bronchial mucosa, reduces local inflammation, and helps improve respiratory function. The procedure is simple, performed in an outpatient setting, and does not require anesthesia. Many patients report improved breathing and reduced symptoms within days of starting therapy.
Treatment usually consists of 3 to 6 sessions, spaced out over days or weeks depending on clinical need. After each session, the patient is monitored and may undergo lung function testing or imaging to assess response. Pulmonary rehabilitation and smoking cessation are strongly recommended to enhance long-term results.
